Cheyne-Stokes Respiration: Clinical Overview
Definition and Recognition
Cheyne-Stokes respiration is a distinctive crescendo-decrescendo breathing pattern with cyclical oscillations in tidal volume and respiratory rate, alternating between periods of hyperventilation and central apneas/hypopneas, most commonly signaling severe heart failure. 1
The formal diagnostic criteria require:
- At least 3 consecutive central apneas and/or central hypopneas separated by the characteristic crescendo-decrescendo pattern 1
- Cycle length of at least 40 seconds (typically 45-90 seconds in heart failure) 1
- Central apnea-hypopnea index ≥5 events/hour recorded over minimum 2 hours of monitoring 1
Pathophysiology: Why It Happens
The underlying mechanism centers on hyperventilation driving arterial CO2 below the apneic threshold, which triggers central apnea during sleep when breathing depends primarily on chemical control rather than behavioral drive. 2, 3
Key contributing factors include:
- High loop gain (exaggerated ventilatory response to blood gas changes) creating oscillatory breathing 3
- Prolonged circulation time in heart failure, delaying feedback from peripheral chemoreceptors 4
- Pulmonary congestion stimulating hyperventilation and lowering baseline PaCO2 2
- Reduced CO2 and O2 body stores causing instability in arterial blood gases 4
Clinical Significance and Prognosis
A central apnea-hypopnea index >30/hour predicts poor survival in heart failure patients and serves as an independent marker of mortality. 1, 2
The pattern causes harm through:
- Recurrent hypoxemia during apneic phases despite compensatory hyperventilation 5, 2
- Sympathetic surges with oscillations in blood pressure and heart rate 2
- Increased risk of ventricular tachycardia 2
- Sleep fragmentation with frequent arousals, leading to daytime sleepiness 4
Longer cycle lengths (73.9-85.7 seconds) correlate with more severe left ventricular dysfunction (ejection fraction <20%), while shorter cycles (49.1-58.9 seconds) occur with less severe dysfunction (LVEF >40%). 1
Etiologies: What Causes It
Primary Cause: Heart Failure
Heart failure with reduced ejection fraction is the dominant cause, occurring in 30-50% of patients with LVEF <40%. 4, 2, 6 The classic presentation includes:
- Long cycle length (45-75 seconds) 1
- Male patients over 60 years 1
- Atrial fibrillation and recurrent pulmonary edema 1
- Orthopnea and paroxysmal nocturnal dyspnea 7
Secondary Causes
Cycle length helps distinguish the underlying etiology:
- Short cycle length (<45 seconds): atrial fibrillation with heart failure, narcotics, pulmonary hypertension, renal failure, high altitude, or stroke 1, 7
- Very short cycle length (~26 seconds): primary central sleep apnea without cardiac disease 1
Stroke is the second major cause, producing central periodic breathing through brainstem dysfunction and impaired respiratory control. 1, 7
Other causes include:
- Neurological disorders disrupting respiratory control centers 7
- Opioid medications depressing respiratory drive 3
- Renal failure through metabolic derangements 7
Clinical Presentation
Patients typically report:
- Excessive daytime sleepiness from sleep fragmentation 4
- Paroxysmal nocturnal dyspnea 4
- Insomnia 4
- Witnessed apneas with snoring 4
Critically, patients may present with perioral cyanosis during apneic phases, especially when prolonged expiratory effort occurs against a closed upper airway. 7
Diagnostic Approach
Polysomnography is essential and must demonstrate absent or markedly reduced respiratory effort during apneic events to distinguish central from obstructive apnea. 7
Required monitoring includes:
- Oxygen saturation to document desaturations 8
- Rib cage and abdominal movement (respiratory inductance plethysmography) showing absent effort 7
- Nasal and oral airflow 7
- Sleep staging via EEG, EOG, and EMG 7
- Electrocardiogram 7
The key polysomnographic distinction: central apneas show absent respiratory effort on effort belts, while obstructive apneas display continued or increased effort against an occluded airway. 7
Common pitfall to avoid: Do not rely on apnea/bradycardia monitors or clinical tools alone—polysomnography with respiratory effort assessment is mandatory to distinguish central from obstructive events. 8, 7
Management Strategy
Primary Intervention
Optimize guideline-based heart failure therapy first—this is the cornerstone of management, as Cheyne-Stokes breathing often improves with effective treatment of the underlying heart failure. 1, 3
Critical warning: Do not suppress Cheyne-Stokes breathing in heart failure patients, as it may represent a compensatory mechanism that should not be targeted after optimal medical therapy. 3
Additional Therapeutic Options
When Cheyne-Stokes respiration persists despite optimal heart failure management:
- Nocturnal oxygen therapy can reduce hypoxemia 4
- Nasal continuous positive airway pressure (CPAP) may be considered 4
- Adaptive servo-ventilation (ASV) is absolutely contraindicated in heart failure patients with reduced ejection fraction due to increased mortality risk 7
Oxygen administration alone without ventilatory support is inadequate, as hypoventilation persists and pulmonary hypertension can develop. 8
Medication Review
Identify and discontinue or reduce opioids and sedative-hypnotics, which can induce or worsen central sleep apnea. 7, 3
Prognostic Implications
In acute cardiogenic pulmonary edema requiring mechanical ventilation, Cheyne-Stokes respiration occurs in 44% of patients but does not predict immediate poor prognosis or in-hospital mortality in this specific setting. 9 However, in chronic heart failure, Cheyne-Stokes breathing with central AHI >30/hour is an independent marker of poor survival and may participate in a vicious cycle further stressing the failing heart. 1, 2
Report the duration of Cheyne-Stokes breathing and number of events in sleep study reports, as longer duration correlates with higher mortality and elevated NT-proBNP. 1